nach oben

Erschienen in:

01.05.2023 | News item

New safety warning for JAK inhibitors in Australia

Erschienen in: Reactions Weekly | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Excerpt

The Australian Therapeutic Goods Administration (TGA) has added a new safety warning for Janus kinase (JAK) inhibitors used for the treatment of chronic inflammatory conditions, after a clinical trial found that tofacitinib increased the risk of serious adverse events. …

New safety warning for medicines used in arthritis and other inflammatory conditions Internet Document : 11 May 2023. Available from: URL: https://www.tga.gov.au/news/safety-alerts/new-safety-warning-medicines-used-arthritis-and-other-inflammatory-conditions

Titel: New safety warning for JAK inhibitors in Australia
Publikationsdatum: 01.05.2023
Verlag: Springer International Publishing
Erschienen in: Reactions Weekly / Ausgabe 1/2023
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-023-39679-6

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2023

Iodine-123

Immune-globulin

Multiple drugs

Itraconazole/omalizumab/prednisone

Dobutamine/furosemide

Illegal edible cannabis products: risk of serious harm if accidentally ingested by children